Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 4/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4472130 | 0.83 | SMN1; SMN2 (0.41) | KCNA5SMN1; SMN2 | |
| SCHEMBL4459076 | 0.82 | KCNA5 (0.38) | KCNA5KCNH2MPOSMN1; SMN2 | |
| SCHEMBL14435433 | 0.81 | CFTR (0.42) | KCNA5KCNH2SMN1; SMN2 | |
| SCHEMBL4472831 | 0.78 | TAAR1 (0.38) | KCNA5KCNH2 | |
| SCHEMBL4458360 | 0.76 | POLB (0.37) | KCNA5KCNH2SMN1; SMN2 | |
| SCHEMBL4464257 | 0.74 | TAAR1 (0.35) | KCNA5KCNH2 | |
| SCHEMBL4469190 | 0.73 | CYP19A1 (0.36) | KCNA5KCNH2 | |
| SCHEMBL4461880 | 0.73 | KCNA5 (0.35) | KCNA5KCNH2 | |
| SCHEMBL4456901 | 0.72 | CYP19A1 (0.49) | KCNA5KCNH2 | |
| SCHEMBL4459300 | 0.72 | KCNA5 (0.36) | KCNA5KCNH2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030043-A1 | Potassium Channel Inhibitors | KCNJ2, KCNH2, KCNH3 | KCNA5 11/4885KCNH2 2/4885MPO 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.